Efficacy and Safety of Oral Budesonide Suspension in Pediatric Patients With Eosinophilic Esophagitis

Article ID	Journal	Published Year	Pages	File Type
3282389	Clinical Gastroenterology and Hepatology	2015	45 Pages	PDF

Abstract

Peak eosinophil counts were significantly reduced throughout the esophagus in pediatric patients with EoE who were given medium-dose and high-dose OBS. There was a large symptom response to placebo that was similar to symptom responses in the OBS groups; symptom response did not distinguish OBS from placebo. ClinicalTrials.gov number, NCT00762073

Keywords

PPI FDA CSS hpf DSQ OBS PEER GERD EoE EOT EoE, Eosinophilic esophagitis gastroesophageal reflux disease GER Gastroesophageal reflux Food and Drug Administration adverse event Proton pump inhibitor high-power field patient-reported outcome PRO symptom score end of treatment Clinical trial Topical corticosteroid